Form 4: Candel Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Charles Schoch, Interim CFO of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On July 17, 2024, Charles Schoch, Interim Chief Financial Officer of Candel Therapeutics, sold 9,884 shares of common stock at a price of $6.4726 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units, as required by the company's mandatory sell-to-cover policy.
- Following the transaction, Schoch directly owns 62,520 shares of Candel Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't provide any strong positive or negative signals about the company's performance or future prospects.
Industry Context
Sales of shares to cover tax obligations are a routine part of equity compensation plans. This transaction is not necessarily indicative of the executive's view of the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction: Charles Schoch sold shares of Candel Therapeutics common stock. |
| 07/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.